Dianthus Therapeutics, Inc. (DNTH) — Financial statements
Income statement, balance sheet, and cash flow for Dianthus Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↓67.3% | 6↑120.6% | 3↓56.0% | 6↑334.8% | 1 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 2↓67.3% | 6↑120.6% | 3↓56.0% | 6↑334.8% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 146↑75.2% | 83↑153.1% | 33↑11.8% | 29↑133.1% | 13 | |
| General & Administrative Expenses | 34↑37.4% | 25↑37.6% | 18↑169.3% | 7↑244.7% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 34↑37.4% | 25↑37.6% | 18↑169.3% | 7↑244.7% | 2 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 180↑66.5% | 108↑112.0% | 51↑41.2% | 36↑148.1% | 15 | |
| Total Costs & Expenses | 180↑66.5% | 108↑112.0% | 51↑41.2% | 36↑148.1% | 15 | |
| Operating Results | ||||||
| Operating Income | -178↓74.7% | -102↓111.5% | -48↓62.2% | -30↓127.0% | -13 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.41↑16.1% | 0.36↑141.5% | 0.15 | 0.00 | |
| EBITDA | -178↓75.4% | -101↓112.2% | -48↓61.8% | -30↓125.9% | -13 | |
| EBIT | -178↓74.7% | -102↓111.5% | -48↓62.2% | -30↓127.0% | -13 | |
| Interest & Other Income | ||||||
| Net Interest Income | 16↓7.2% | 17↑264.5% | 5↑316.1% | 1↑1045.0% | 0.10 | |
| Interest Income | 16↓7.2% | 17↑264.5% | 5↑316.1% | 1↑1045.0% | 0.10 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 16↓7.7% | 17↑265.8% | 5↑275.8% | 1↑5443.5% | -0.02 | |
| Income Before Tax | -162↓91.1% | -85↓95.1% | -44↓53.0% | -28↓117.2% | -13 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -162↓91.1% | -85↓95.1% | -44↓53.0% | -28↓117.2% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -162↓91.1% | -85↓95.1% | -44↓53.0% | -28↓117.2% | -13 | |
| Bottom-Line Net Income | -162↓91.1% | -85↓95.1% | -44↓53.0% | -28↓117.2% | -13 | |
| EPS (Basic) | -4.20↓64.7% | -2.55↑69.8% | -8.45↓11.2% | -7.60↓99.0% | -3.82 | |
| EPS (Diluted) | -4.20↓64.7% | -2.55↑69.8% | -8.45↓11.2% | -7.60↓99.0% | -3.82 | |
| Weighted Average Shares | 38↑13.4% | 33↑546.4% | 5↑37.5% | 4↑9.1% | 3 | |
| Weighted Average Diluted Shares | 38↑13.4% | 33↑546.4% | 5↑37.5% | 4↑9.1% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.